Physician profile
Ann E Schmitt
NPI 1801359666
$431.67
in general payments reported to CMS, 2019-2025
17 companies · $20.01 in 2025
The $20.01 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $308 · 2023: $84.55 · 2024: $19.37 · 2025: $20.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $92.60 · Debt Forgiveness: $31.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $92.60 |
| Debt Forgiveness | $31.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $45.10 | 2022-2023 | Aplenzin, Wellbutrin |
| Exact Sciences Corporation | $39.38 | 2024-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $35.32 | 2022 | |
| Baxter Healthcare | $31.33 | 2023 | |
| Sanofi-Aventis U.S. LLC | $30.75 | 2022 | |
| Abbvie INC. | $30.53 | 2022 | |
| Glaxosmithkline, LLC. | $28.10 | 2022 | |
| Novartis Pharmaceuticals Corporation | $26.86 | 2022 | |
| Amgen INC. | $25.45 | 2023 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $20.13 | 2022 | |
| Alkermes, INC. | $19.83 | 2022 | |
| Mylan Specialty L.P. | $18.80 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.47 | 2022 | |
| Novo Nordisk INC | $17.15 | 2022 | |
| Lilly USA, LLC | $16.38 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $14.21 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $13.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Schmitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.